These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 22537261)

  • 1. mTOR inhibitors: a myth, a cure for cancer or something in between?
    Wong G; Chapman JR; Craig JC
    Am J Transplant; 2012 May; 12(5):1075-6. PubMed ID: 22537261
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer.
    Campbell SB; Walker R; Tai SS; Jiang Q; Russ GR
    Am J Transplant; 2012 May; 12(5):1146-56. PubMed ID: 22420843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor regression and sirolimus-based therapy in lung transplantation.
    Hillen U; Griewank K; Sommerwerck U; Baba HA; Schadendorf D
    J Heart Lung Transplant; 2013 Sep; 32(9):938-9. PubMed ID: 23953823
    [No Abstract]   [Full Text] [Related]  

  • 4. Transplantation: Sirolimus for secondary SCC prevention in renal transplantation.
    Halleck F; Budde K
    Nat Rev Nephrol; 2012 Dec; 8(12):687-9. PubMed ID: 23026948
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of Checkpoint Inhibitors in a Kidney Transplant Recipient with Metastatic Cancer.
    Ong SC; Mannon RB
    Clin J Am Soc Nephrol; 2020 Aug; 15(8):1190-1192. PubMed ID: 32205320
    [No Abstract]   [Full Text] [Related]  

  • 6. mTOR Inhibition and Clinical Transplantation: Kidney.
    Flechner SM
    Transplantation; 2018 Feb; 102(2S Suppl 1):S17-S18. PubMed ID: 28230636
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of sirolimus in kidney transplantation.
    Podbielski J; Schoenberg L
    Prog Transplant; 2001 Mar; 11(1):29-32. PubMed ID: 11357554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus: not so sparing in the Spare-the-Nephron trial.
    Shamseddin MK; Gupta A
    Kidney Int; 2011 Jun; 79(12):1379; author reply 1379-80. PubMed ID: 21625260
    [No Abstract]   [Full Text] [Related]  

  • 9. Sirolimus and skin-cancer prevention in kidney transplantation.
    Smak Gregoor PJ
    N Engl J Med; 2012 Oct; 367(16):1565; author reply 1565-6. PubMed ID: 23075186
    [No Abstract]   [Full Text] [Related]  

  • 10. Prompt response of advanced cutaneous squamous cell carcinoma to cemiplimab in a kidney transplant patient receiving treatment with everolimus.
    Gambichler T; Hessam S; Lüttringhaus T; Boms S
    Clin Exp Dermatol; 2022 Mar; 47(3):608-609. PubMed ID: 34767651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus after kidney transplantation.
    Sharif A
    BMJ; 2014 Nov; 349():g6808. PubMed ID: 25424845
    [No Abstract]   [Full Text] [Related]  

  • 12. The ups and downs of sirolimus in kidney transplantation, and the importance of reporting negative findings.
    van Gelder T
    Neth J Med; 2007 Jan; 65(1):3-4. PubMed ID: 17293633
    [No Abstract]   [Full Text] [Related]  

  • 13. Carcinoma "en Cuirasse" from cutaneous squamous cell carcinoma in a renal transplant patient.
    Lorentzen HF
    Transplantation; 2008 Apr; 85(7):1065-6. PubMed ID: 18408591
    [No Abstract]   [Full Text] [Related]  

  • 14. Sirolimus to replace calcineurin inhibitors? Too early yet.
    Cravedi P; Ruggenenti P; Remuzzi G
    Lancet; 2009 Apr; 373(9671):1235-6. PubMed ID: 19362662
    [No Abstract]   [Full Text] [Related]  

  • 15. Sirolimus is effective for prevention of acute rejection in primary mismatched renal allograft recipients.
    Ponticelli C
    Transplant Proc; 2001; 33(1-2):1031-2. PubMed ID: 11267177
    [No Abstract]   [Full Text] [Related]  

  • 16. The pros and the cons of mTOR inhibitors in kidney transplantation.
    Ponticelli C
    Expert Rev Clin Immunol; 2014 Feb; 10(2):295-305. PubMed ID: 24377908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppressive Medications and Squamous Cell Skin Carcinoma: Nested Case-Control Study Within the Skin Cancer after Organ Transplant (SCOT) Cohort.
    Coghill AE; Johnson LG; Berg D; Resler AJ; Leca N; Madeleine MM
    Am J Transplant; 2016 Feb; 16(2):565-73. PubMed ID: 26824445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat.
    Vogelbacher R; Meister S; Gückel E; Starke C; Wittmann S; Stief A; Voll R; Daniel C; Hugo C
    Nephrol Dial Transplant; 2010 Nov; 25(11):3764-73. PubMed ID: 20466656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus vs azathioprine.
    Gleadle JM; Mason PD
    Lancet; 2000 Nov; 356(9243):1768-9. PubMed ID: 11095282
    [No Abstract]   [Full Text] [Related]  

  • 20. Rationale for using belatacept in combination with sirolimus.
    Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
    Transplant Proc; 2010 Nov; 42(9 Suppl):S29-31. PubMed ID: 21095447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.